Richard Trauger

Richard Trauger has over 30 years of experience in the biotech industry. Richard is currently the Executive Director of Translational Science at Oncolytics Biotech Inc. Prior to this, they worked at Viracta Therapeutics, Inc. as the Senior Director of Translational Medicine, where they managed pre-clinical studies and assessed new opportunities for the company's proprietary molecule Nanatinostat. Before that, Richard was self-employed as a Research and Development Consultant, focusing on developing a treatment for oral mucositis. At Ansun Biopharma, Inc., they served as the Director of Virology, overseeing lead compound research and development. Richard was also the Chief Scientific Officer at CytoDyn Inc. and played a key role in the acquisition of PRO140, a novel monoclonal antibody for the treatment of HIV. Richard has held various other positions throughout their career, including Director of Scientific Information at CytoDyn Inc., Vice President of R&D at MetaCytoLytics, and Senior Director of Cancer and Infectious Disease at Hollis Eden Pharmaceuticals. Richard started their career at The Immune Response Corporation, where they held the position of Director of Infectious Disease and Oncology and managed the immunology laboratory for their therapeutic vaccine program for HIV.

Richard Trauger completed their education at the University of South Carolina School of Medicine from 1981 to 1986. During this period, they pursued a Doctor of Philosophy (Ph.D.) degree in Biomedical Science.